21 June 2013Americas

Federal Circuit holds Novo Nordisk patent invalid

The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk